William D Kenfield DDS LLC Patient Information Patient Name_____________________________________________ Phone# ( )____________Cell# ( )_____________ Address ______________________________________ City ________________________State ____ Zip ________________ Social Security #_______________________Birth Date__________________ Male  Female  Marital Status__________ Parent/Guardian
Curriculum vitaeCURRICULUM VITAE
PAUL STANLEY LIETMAN, M.D., PH.D.
Director of the Division of Clinical Pharmacology (a division of the Department of Medicine and the Department of Pharmacology and Molecular Science) and holder of the Wellcome Chair in Clinical Pharmacology for 29 years (1972-2001). During this time the Division of Clinical Pharmacology developed unparalleled strength in the areas of antimicrobial chemotherapy and drug development for antibacterial, antiviral, and antiparasitic drugs. Specific examples of studies in drug development performed by Dr. Lietman with his colleagues in the Division of Clinical Pharmacology include the following: • The first prospective, randomized, double masked, and controlled clinical trials comparing two antibiotics in the management of patients with sepsis or presumed sepsis (Smith et al.,1977, Smith et al.,1980) The use of data from three of these studies to define the risk factors for aminoglycoside nephrotoxicity and ototoxicity (Moore et al.,1984) Preclinical studies to help define the mechanisms of nephrotoxicity of aminoglycoside antibiotics (Lipsky 1980) Phase I and early Phase II studies of the acyclovir, the anti-herpesvirus drug that opened the era of antiviral chemotherapy (Laskin et al.,1982, Studies of the prophylactic value of acyclovir in both bone marrow transplant recipients and leukemia patients (Saral; et al.,1981, Saral et First-time-in-human studies of several antiviral drugs currently marketed for HIV and hepatitis B infections (Barditch-Crovo et al.,1997, Deeks et Studies of a biologic response modifier, interferon alpha, in humans using surrogate markers (resistance to mononuclear viral infectivity and an enzyme induced by interferon alpha, oligo 2-5 adenylate synthetase (Barouki et al.,1987, Hendrix et al.,1995) Studies that laid to rest the currently held view of the value of oral dextran sulfate for HIV infection using surrogate markers of dextran sulfate’s anticoagulant effect and blood levels of dextran sulfate (Lorentsen et Studies of drug interactions between probenecid and zidovudine, defining the favorable pharmacokinetic effects of probenecid on the cutaneous toxicity associated with this drug interaction (Kornhauser et al.,1989) Creation of an in vitro hollow fiber cartridge system that allows the assessment of the interface between the pharmacokinetics and the Development of a rigorous methodology for the testing of the bioequivalence of albuterol delivery by metered dose inhalers (Creticos et In addition to these examples from published studies, Dr. Lietman has a rich experience in the organization of and leadership of new clinical pharmacology and clinical research entities. These include: • Built a very strong Division of Clinical Pharmacology Created a Drug Development Unit within the Division of Clinical Pharmacology that has worked with and been supported by the pharmaceutical industry, the NIH, the FDA and the Army and recruited Dr. Craig Hendrix to be Director of that unit. Created a Drug Analysis Laboratory within the Drug Development Unit and recruited Dr. Fayez Hamzeh to be director of that laboratory. Created a new and novel position within the Division of Clinical Pharmacology called the “Hospital Pharmacologist” (analogous to the Hospital Epidemiologist but with a focus on drug use instead of infections) and recruited Dr. Brent Petty to that position. Was one of the founders of the JHU Graduate Training Program in Clinical Investigation (GTPCI) and still serves on the council overseeing that As the founding Director of Research and Education created and managed a new entity called Johns Hopkins Singapore. Served for five years on the Hopkins Committee on Conflict of Interest. Served for several years as the Associate Director of the Adult Inpatient Served for many (15+) years on the Institutional Review Board at Johns Hopkins and chaired one of the Johns Hopkins Medicine IRBs for 3 years. Serving as a consultant to the Government of Trinidad and Tobago and the University of Trinidad and Tobago in the creation of a Caribbean Pivotal in the creation and maintenance of academic relationships between The Johns Hopkins Pediatrics Department and the Children’s Hospital of Fudan University and between the Johns Hopkins Basic Sciences Institute and the Shanghai Medical College of Fudan University.
Voices in the Wilderness As history edged toward the twentieth century, the German philosopher Friedrich Nietzsche wrote his parable of the madman who stormed into the marketplace with lantern in hand crying, “I seek God! I seek God!” Atheists in the audience made fun: “‘Has he got lost?’ asked one. ‘Did he lose his way like a child?’ asked another. ‘Or is he hiding? Is he